Proactively Managing Toxicities in RCC IO/TKI Combinations: Insights and Recommendations
Panelists discuss essential patient education when initiating combination regimens for RCC, addressing overlapping and unique toxicity considerations in IO/TKI combinations, counseling strategies for monitoring and communicating potential adverse events (AEs), key AEs for patients to watch for, and strategies for proactive toxicity mitigation and management.
Video content above is prompted by the following:
- From a nursing perspective, what patient education is essential when initiating these combination regimens?
- When treating patients with RCC with IO/TKI combinations, what are the overlapping and unique toxicity considerations?
- How do you counsel patients about monitoring and communicating regarding potential adverse events? Which AEs are most important for patients to look out for?
- What strategies do you recommend for proactive toxicity mitigation and management?
- From a patient perspective, what information is essential for patients to understand when receiving pembrolizumab plus lenvatinib?
- Which adverse effects did you experience while on treatment, and how did you manage these?
- What was the role of your care team in managing adverse effects and counseling you throughout treatment?
Recent Videos
Related Content
